• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
FTT
Click for more information
0.00% 0.5¢

FACTOR THERAPEUTICS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
FTT Receipt of R&D tax rebatePRICE SENSITIVE22/03/19
FTT Response to ASX QueryPRICE SENSITIVE04/03/19
FTT Annual Report for Financial Year to 31 Dec 2018PRICE SENSITIVE21/02/19
FTT Placement completed to support future direction of FactorPRICE SENSITIVE05/02/19
FTT Update regarding anticipated R&D tax incentive rebatePRICE SENSITIVE04/02/19
FTT Appendix 4C - December quarterPRICE SENSITIVE31/01/19
FTT Management ChangePRICE SENSITIVE25/01/19
FTT Results of Phase 2 Clinical TrialPRICE SENSITIVE14/11/18
FTT Trading HaltPRICE SENSITIVE13/11/18
FTT Appendix 4C - September 2018 QuarterPRICE SENSITIVE19/10/18
FTT Factor Therapeutics Appoints Transaction AdvisorPRICE SENSITIVE16/10/18
FTT Last patient completes treatment in VLU Ph 2 Clinical TrialPRICE SENSITIVE04/10/18
FTT Half Yearly Report and AccountsPRICE SENSITIVE23/08/18
FTT Appendix 4C - June 2018 quarterPRICE SENSITIVE27/07/18 download Created with Sketch. 139.49KB
FTT Recruitment complete in VF00102 Phase 2 clinical trialPRICE SENSITIVE16/07/18 download Created with Sketch. 65.21KB
FTT Screening to close as clinical trial nears completionPRICE SENSITIVE26/06/18 download Created with Sketch. 88.33KB
FTT Clinical Trial UpdatePRICE SENSITIVE14/06/18 download Created with Sketch. 257.19KB
FTT Receipt of $1.23M R&D tax incentivePRICE SENSITIVE15/05/18
FTT Clinical trial update - recruitment enters final phasePRICE SENSITIVE14/05/18
FTT Appendix 4C - March 2018 QuarterPRICE SENSITIVE26/04/18
FTT Clinical Trial update - March quarterPRICE SENSITIVE10/04/18
FTT Rights Issue Entitlement Offer Information BookletPRICE SENSITIVE14/03/18
FTT Factor announces fully underwritten entitlement offerPRICE SENSITIVE14/03/18
FTT Investor PresentationPRICE SENSITIVE14/03/18
FTT Rights Issue Entitlement Offer - Cleansing NoticePRICE SENSITIVE14/03/18
FTT Trading HaltPRICE SENSITIVE12/03/18
FTT Clinical Trial UpdatePRICE SENSITIVE05/03/18
FTT Appendix 4E Preliminary Final ReportPRICE SENSITIVE22/02/18
FTT Appendix 4C - December 2017 QuarterPRICE SENSITIVE25/01/18
FTT Clinical Trial UpdatePRICE SENSITIVE18/01/18
FTT Shareholder UpdatePRICE SENSITIVE15/01/18
FTT Factor receives $3.1M R&D tax rebatePRICE SENSITIVE05/12/17
FTT 50% recruitment reached in VF00102 Clinical TrialPRICE SENSITIVE29/11/17
FTT Clinical Trial UpdatePRICE SENSITIVE02/11/17
FTT Appendix 4C for the September QuarterPRICE SENSITIVE30/10/17
FTT Shareholder communication - clinical trial updatePRICE SENSITIVE05/10/17
FTT Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE15/08/17
FTT Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
FTT Appointment of Dr. Rosalind Wilson as CEOPRICE SENSITIVE22/05/17
FTT Appendix 4CPRICE SENSITIVE27/04/17
FTT Phase II clinical trial progress updatePRICE SENSITIVE07/04/17
FTT Half Year AccountsPRICE SENSITIVE15/02/17
FTT Appendix 4C - December 2016 quarterPRICE SENSITIVE24/01/17
FTT Phase II Clinical Trial - First Patient InPRICE SENSITIVE20/12/16
FTT Collaboration and IP option agreement with Monash UniversityPRICE SENSITIVE22/11/16
FTT FDA - lift of clincial holdPRICE SENSITIVE07/11/16
FTT Appendix 4C for the September Quarter-FTT.AX PRICE SENSITIVE27/10/16
FTT Submission of IND amendments for Phase II study-FTT.AX PRICE SENSITIVE10/10/16
FTT Completion of Manufacturing-FTT.AX PRICE SENSITIVE09/09/16
FTT Appendix 4E - Preliminary Final Report-FTT.AX PRICE SENSITIVE17/08/16
FTT Formation of Medical Advisory Board-FTT.AX PRICE SENSITIVE03/08/16
FTT Appendix 4C - quarterly-FTT.AX PRICE SENSITIVE28/07/16
FTT Clinical Trial Update-FTT.AX PRICE SENSITIVE15/06/16
FTT Receipt of R&D tax rebate
22/03/19PRICE SENSITIVE
FTT Response to ASX Query
04/03/19PRICE SENSITIVE
FTT Annual Report for Financial Year to 31 Dec 2018
21/02/19PRICE SENSITIVE
FTT Placement completed to support future direction of Factor
05/02/19PRICE SENSITIVE
FTT Update regarding anticipated R&D tax incentive rebate
04/02/19PRICE SENSITIVE
FTT Appendix 4C - December quarter
31/01/19PRICE SENSITIVE
FTT Management Change
25/01/19PRICE SENSITIVE
FTT Results of Phase 2 Clinical Trial
14/11/18PRICE SENSITIVE
FTT Trading Halt
13/11/18PRICE SENSITIVE
FTT Appendix 4C - September 2018 Quarter
19/10/18PRICE SENSITIVE
FTT Factor Therapeutics Appoints Transaction Advisor
16/10/18PRICE SENSITIVE
FTT Last patient completes treatment in VLU Ph 2 Clinical Trial
04/10/18PRICE SENSITIVE
FTT Half Yearly Report and Accounts
23/08/18PRICE SENSITIVE
FTT Appendix 4C - June 2018 quarter
27/07/18PRICE SENSITIVE download Created with Sketch. 139.49KB
FTT Recruitment complete in VF00102 Phase 2 clinical trial
16/07/18PRICE SENSITIVE download Created with Sketch. 65.21KB
FTT Screening to close as clinical trial nears completion
26/06/18PRICE SENSITIVE download Created with Sketch. 88.33KB
FTT Clinical Trial Update
14/06/18PRICE SENSITIVE download Created with Sketch. 257.19KB
FTT Receipt of $1.23M R&D tax incentive
15/05/18PRICE SENSITIVE
FTT Clinical trial update - recruitment enters final phase
14/05/18PRICE SENSITIVE
FTT Appendix 4C - March 2018 Quarter
26/04/18PRICE SENSITIVE
FTT Clinical Trial update - March quarter
10/04/18PRICE SENSITIVE
FTT Rights Issue Entitlement Offer Information Booklet
14/03/18PRICE SENSITIVE
FTT Factor announces fully underwritten entitlement offer
14/03/18PRICE SENSITIVE
FTT Investor Presentation
14/03/18PRICE SENSITIVE
FTT Rights Issue Entitlement Offer - Cleansing Notice
14/03/18PRICE SENSITIVE
FTT Trading Halt
12/03/18PRICE SENSITIVE
FTT Clinical Trial Update
05/03/18PRICE SENSITIVE
FTT Appendix 4E Preliminary Final Report
22/02/18PRICE SENSITIVE
FTT Appendix 4C - December 2017 Quarter
25/01/18PRICE SENSITIVE
FTT Clinical Trial Update
18/01/18PRICE SENSITIVE
FTT Shareholder Update
15/01/18PRICE SENSITIVE
FTT Factor receives $3.1M R&D tax rebate
05/12/17PRICE SENSITIVE
FTT 50% recruitment reached in VF00102 Clinical Trial
29/11/17PRICE SENSITIVE
FTT Clinical Trial Update
02/11/17PRICE SENSITIVE
FTT Appendix 4C for the September Quarter
30/10/17PRICE SENSITIVE
FTT Shareholder communication - clinical trial update
05/10/17PRICE SENSITIVE
FTT Appendix 4E and Full Year Statutory Accounts
15/08/17PRICE SENSITIVE
FTT Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
FTT Appointment of Dr. Rosalind Wilson as CEO
22/05/17PRICE SENSITIVE
FTT Appendix 4C
27/04/17PRICE SENSITIVE
FTT Phase II clinical trial progress update
07/04/17PRICE SENSITIVE
FTT Half Year Accounts
15/02/17PRICE SENSITIVE
FTT Appendix 4C - December 2016 quarter
24/01/17PRICE SENSITIVE
FTT Phase II Clinical Trial - First Patient In
20/12/16PRICE SENSITIVE
FTT Collaboration and IP option agreement with Monash University
22/11/16PRICE SENSITIVE
FTT FDA - lift of clincial hold
07/11/16PRICE SENSITIVE
FTT Appendix 4C for the September Quarter-FTT.AX
27/10/16PRICE SENSITIVE
FTT Submission of IND amendments for Phase II study-FTT.AX
10/10/16PRICE SENSITIVE
FTT Completion of Manufacturing-FTT.AX
09/09/16PRICE SENSITIVE
FTT Appendix 4E - Preliminary Final Report-FTT.AX
17/08/16PRICE SENSITIVE
FTT Formation of Medical Advisory Board-FTT.AX
03/08/16PRICE SENSITIVE
FTT Appendix 4C - quarterly-FTT.AX
28/07/16PRICE SENSITIVE
FTT Clinical Trial Update-FTT.AX
15/06/16PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
ASX Market Open: Bessent hype, Lebanon ceasefire hopes push Aus markets higher | November 26, 2024 A rollercoaster ride in on Wall Street @ capped by a Dow Jones record @ and reports of an impending Israel-Hezbollah ceasefire have both buoyed Australian futures, with the ASX 200 expected to rise 0.17% at open today.Forget @Trump trade;” the U.S. rally has been super-charg...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.